BICO News Feed

Discover the latest news from our business areas.

BICO joins The North American 3Rs Collaborative’s (NA3RsC) Microphysiological Systems (MPS) Initiative

Share on facebook
Share on twitter
Share on linkedin

BICO has officially joined the NA3RsC MPS Initiative, a collaboration to increase industry adoption and regulatory acceptance of microphysiological technologies with the ultimate goal of refining, reducing, and replacing research animals. An initiative that closely aligns with work done by BICO Bioprinting and its subsidiaries.

The BICO Group joins 40 other institutions in this initiative, with the goal of increasing the adoption of MPS technologies that could potentially replace or reduce some animal models that are used for drug development. MPS includes tissue models such as spheroids, organoids, and organs-on-chips. This mission directly ties to the work of several of the BICO Group Companies, especially those within the bioprinting business area like CELLINK, MatTek, Advanced Biomatrix  and Visikol.


The North American 3Rs Collaborative (NA3RsC) is a non-profit organization whose mission is to advance science, innovation, and research animal welfare through collaborative 3Rs efforts (refine, reduce, and replace). The group’s initiatives are focused on implementing efforts pertaining to the 3R principle. A principle with ample evidence of effectiveness, potential for big impact, and ultimately, methods that are realistic considering the status quo and current research trends.


The MPS initiative focuses on four main areas: Conference and Education about MPS Technology, Technology Hub, Interacting with Pharmaceutical Companies, and Regulatory Acceptance.


To find out more about this initiative, please visit

More news

June 27, 2022 | Cytena

CYTENA is officially the Innovator of the Year 2022

June 7, 2022 | Cytena

CYTENA enters long term OEM supply agreement with PAIA and launches the F.QUANT Titer high-throughput titer quantification assays for antibodies and Fc fusion proteins

June 6, 2022 | Cellink

Bioprinted Ear Successfully Transplanted into Patient

June 1, 2022 | Dispendix


June 1, 2022 | Scienion

SCIENION bestellt Frauke Hein als CEO

June 1, 2022 | Scienion

SCIENION Appoints Frauke Hein as CEO

May 30, 2022 | Dispendix

BICO Management Summit 2022

May 24, 2022 | Bico

Biosero, a Part of BICO Biosciences Is Awarded a New Patent for Laboratory Automation Scheduling Software

May 24, 2022 | Cellenion

Breakfast with Cellenion

May 16, 2022 | Bico

BICO joins The North American 3Rs Collaborative’s (NA3RsC) Microphysiological Systems (MPS) Initiative

May 12, 2022 | Bico

BICO Group Adds Senior IR Manager to Its Executive Management

May 11, 2022 | Dispendix

SLAS Europe 2022 – Dublin

May 6, 2022 | Cellenion

cellenONE Training & Workshop – June 2022

May 6, 2022 | Cellink

BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology

May 5, 2022 | Cellink

CELLINK Announces CTR Scientific as Exclusive Distributor in Mexico

May 3, 2022 | Cytena

CYTENA and ExcellGene to Develop Automated Workflows for Biotherapeutics Cell Line Development

April 13, 2022 | Scienion

SCIENION GmbH feiert Grundsteinlegung für neue Unternehmenszentrale in Berlin Adlershof

March 3, 2022 | Cellenion

Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence